Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.
586 articles
Showing 265–269 of 269 articles
Kircheis, R.; Wightman, L.; Wagner, E
PEI is one of the most effective non-viral gene delivery polymers, but its efficacy, toxicity, and in vivo behaviour depend strongly on molecular weight, branching, particle size, surface charge, and modifications. This review addresses how PEI/DNA complexes can be modified with targeting ligands, shielding agents…
Read the articleGodbey, W. T.; Wu, K. K.; Mikos, A. G
Gene therapy still lacks safe and efficient delivery vectors. PEI has emerged as a promising non-viral polycation because it condenses DNA and mediates endosomal escape, but its transfection mechanism, targeting potential, and toxicity require clearer understanding. This review summarises PEI chemistry, PEI/DNA…
Read the articleHope Mj, Mui B, Ansell S, Ahkong Qf
Polymeric nucleic acid drugs—plasmid DNA, antisense oligonucleotides, and ribozymes—require protection from nucleases and efficient intracellular delivery to cytoplasm/nucleus. Viral vectors are efficient but immunogenic and safety-limited; non-viral cationic lipid systems are promising, but the mechanism of…
Read the articleFelgner Pl, Ringold Gm
Existing polynucleotide delivery methods—calcium phosphate, DEAE-dextran, electroporation, retroviral vectors—had limitations in convenience, reproducibility, efficiency, and applicability across cell types. A simple, broadly effective cationic liposome reagent was needed for DNA and RNA transfection of mammalian…
Read the articleThe transferrin receptor (TfR) is overexpressed on many cancer cells and is efficiently internalised, making it a useful target for delivering small-molecule drugs and nucleic acid therapeutics while reducing non-target effects. The review summarises TfR biology, Tf-lipoplex development, and therapeutic applications…
Read the articleWe co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
